Abstract: A tomato composition obtained from tomato juice having the following composition in percentage by weight: dry residue>20% up to 99%, water<80% down to 1%; 100% being the sum of the two components, wherein the among of water insoluble solids in the dry residue ranges in percentage by weight from 18% to 70%.

Abstract: Tomato products obtained from tomato juice or tomato passata having the following composition in percentage by weight: dry residue ?5.5-20%, water 94.5-80%, 100% being the sum of the two components, wherein the amount of water insoluble and water soluble solids in the dry residue ranges in percentage by weight: Water insoluble solids from 18% to 70%, Water soluble solids from 82% to 30%, the sum of the two components being 100% of the dry residue.

Abstract: A process for treating tomato concentrates obtainable by concentration by evaporation, having a dry residue in percentage by weight higher than 15%, generally at least of about 18%, comprising the following steps: I) mixing of the tomato concentrate (component a)) with water (component b)); II) liquid separation by a separation solid-liquid apparatus, wherein the mass to be filtered is maintained under a slow stirring; III) addition of water and/or serum to the solid mass obtained in II).

Abstract: Tomato products obtained from tomato juice or tomato passata having the following composition in percentage by weight: dry residue 5.5-20%, water 94.5-80%, 100% being the sum of the two components, wherein the amount of water-insoluble and water-soluble solids in the dry residue ranges in percentage by weight: Water-insoluble solids from 18% to 70% Water-soluble solids from 82% to 30%, the sum of the two components being 100% of the dry residue.

Abstract: A process for treating tomato concentrates obtainable by concentration by evaporation, having a dry residue in percentage by weight higher than 15%, generally at least of about 18%, comprising the following steps: I) mixing of the tomato concentrate (component a)) with water (component b)); II) liquid separation by a separation solid-liquid apparatus, wherein the mass to be filtered is maintained under a slow stirring; III) addition of water and/or serum to the solid mass obtained in II).

Abstract: A tomato composition obtained from tomato juice having the following composition in percentage by weight: dry residue >20% up to 99%, water <80% down to 1%; 100% being the sum of the two components, wherein the among of water insoluble solids in the dry residue ranges in percentage by weight from 18% to 70%.

Abstract: Tomato products obtained from tomato juice or tomato passata having the following, composition in percentage by weight: —dry residue 5.5-20%, —water 94.5-80%, 100% being the sum of the two components, wherein the amount of water insoluble and water soluble solids in the dry residue ranges in percentage by weight: —water insoluble solids from 18% to 70%. —Water soluble solids from 82% to 30% The sum of the two components being 100% of the dry residue.

Abstract: The present invention refers to pharmaceutical compositions containing monosialoganglioside GM1 or a derivative thereof, namely, the inner ester AGF2 and the methyl ester AGF4, suitable for the treatment of Parkinson's disease. A further object of the present invention is a therapy for Parkinson's disease based on the associated administration of the aforesaid compounds and, in addition, the N-dichloroacetyl lyso GM1 (LIGA 20) with known pharmaceuticals active in the aforesaid treatment, in particular with L-dopa and/or BDNF.

Abstract: The present invention involves compositions for use as granular bone replacements. The compositions of the present invention are comprised of hyaluronic acid esters or salts of hyaluronic acid in association with a pharmacologically active compound wherein the molecular weight of the hyaluronic acid is below 250,000 and either artificial or natural bone granules. The present invention further involves a method of promoting the growth or repair of damaged or defective bones in either humans or animals using the compositions of hyaluronic acid derivatives and bone granules.

Abstract: Novel N-acyl-lysogangliosides obtained from gangliosides by deacyation of the ceramide group, wherein the acyl group is derived from an aliphatic acid having from 2 to 24 carbon atoms, substituted by one or more polar groups. The N-acyl-lysogangliosides of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.

Abstract: The present invention involves compositions for use as granular bone replacements. The compositions of the present invention are comprised of hyaluronic acid esters or salts of hyaluronic acid in association with a pharmacologically active compound wherein the molecular weight of the hyaluronic acid is below 250,000 and either artificial or natural bone granules. The present invention further involves a method of promoting the growth or repair of damaged or defective bones in either humans or animals using the compositions of hyaluronic acid derivatives and bone granules.

Abstract: Pharmaceutical preparations are described, comprised of salts of hyaluronic acid with a basic anesthetic containing aliphatics and/or amino groups, particularly salts with benzydamine or bupivacaine.

Abstract: The present invention is directed to a microsphere for the controlled release of a biologically active molecule which comprises a biologically active molecule and an ester of hyaluronic acid or mixtures of said esters of hyaluronic acids, and wherein said biologically active molecule is surrounded by or adhered to said ester of hyaluronic acid, and wherein said microsphere has a diameter of between 1 .mu.m to 100 .mu.m.

Abstract: The present invention is directed to a microsphere for the controlled release of a biologically active molecule which comprises a biologically active molecule and an ester of hyaluronic acid or mixtures of said esters of hyaluronic acids, and wherein said biologically active molecule is surrounded by or adhered to said ester of hyaluronic acid, and wherein said microsphere has a diameter of between 1 .mu.m to 100 .mu.m.

Abstract: Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections.

Abstract: The present invention is drawn to medical devices comprising biodegradable guide channels for use in the repair and regeneration of nerve tissue. The guide channels of the present invention comprise interlaced threads imbedded in a matrix, wherein both the matrix and the threads comprise biocompatible and bioabsorbable esters of hyaluronic acid. The matrix of the present invention further optionally comprises biologically or pharmacologically active factors in association with the guide channels.

Abstract: Disclosed are derivatives of gangliosides and of N-acyl-N-lyso-gangliosides, of N'-acyl-N'-lyso-gangliosides and N,N'-di- or poly-acyl-N,N'-di-lyso-gangliosides, in which at least one of the hydroxyl groups in the saccharide, sialic or ceramide residues is esterified with sulfuric acid, functional derivatives thereof, and their salts with either inorganic or organic bases and the acid addition salts, except persulfated derivatives at the hydroxyl, sialic and ceramide groups of the GM.sub.1, GD.sub.1a, GD.sub.1b and GT.sub.1b gangliosides. Such compounds have antineurotoxic and neurotogenic activity and may therefore be used in pharmaceutical preparations. Also a marked modulating effect on the expression of the CD.sub.4 molecule in immune system cells has been shown.

Abstract: Biomaterials are disclosed comprised of biodegradable, biocompatible, and bioabsorbable non-woven fabric materials for use in surgery for the guided regeneration of tissues. The non-woven fabric materials constitute threads embedded in a matrix, wherein both the matrix and the threads constitute auto-crosslinked hyaluronic acid.

Abstract: Semisynthetic analogues of gangliosides selected from the group consisting of N-sulfo-, N-hydrocarbyl-sulfonyl- and N-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N'-acyl derivatives thereof, N'-sulfo-, N'-hydrocarbylsulfonyl- and N'-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N-acyl derivatives thereof, N,N'-di or polysulfo-N,N'-di- or poly-lyso-gangliosides, N,N'-di- or polyhydrocarbylsulfonyl-N,N'-di- or poly-lyso-gangliosides and N,N'-di- or polyhydrocarbyloxy-N,N'-di- or poly-lyso-gangliosides, and functional derivatives thereof, and salts of these compounds, have protective activity against neurotoxicity induced by excitatory amino acids and are foreseen to be used in therapy in the nervous system and in modulating of the expression of determinants such as CD.sub.4 on the surface of human cells in the immune system.

Abstract: Novel derivatives of lysophingolipids free from sialic acids which are N-acyllysosphingolipids having one of the two formulae: ##STR1## in which -A- stands for the group --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, n.sub.1 is a whole number of between 6 and 18, n.sub.2 is a whole number of between 11 and 15, X is a hydrogen atom or the residue of a monosaccharide or a disaccharide or phosphorylcholine and R represents an alkyl radical derived from a saturated or unsaturated aliphatic carboxylic acid having from 2 to 24 carbon atoms substituted by one or more polar groups. The lysosphingolipid derivatives of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.